Sumatriptan-naproxen and Butalbital - Medscape News

Objectives.— The primary objective was to compare the efficacy of a sumatriptan and naproxen combination medication (SumaRT/Nap—85 mg sumatriptan and 500 mg naproxen sodium), a butalbital-containing combination medication (BCM—50 mg ...

Sumatriptan/Naproxen helpful in treating teens' migraines - medicalxpress.com

(HealthDay) -- Treatment with sumatriptan and naproxen sodium (suma/nap) is well tolerated and effective in reducing migraine pain in adolescents, according to a study published online May 14 in Pediatrics. Frederick J. Derosier, D.O., from ...

Finally, effective migraine relief for teenagers? - ModernMedicine

The combination of sumatriptan and naproxen sodium safely and effectively relieves acute adolescent migraine pain and its associated symptoms compared with placebo, according to the results of a new randomized trial. Billed as the first large ...

Sumatriptan-naproxen combo relieves adolescent migraine pain - SmartBrief

U.S. researchers tested three doses of sumatriptan and naproxen sodium in teens with migraines and found that all doses were well tolerated and effective in relieving pain two hours after dosing. The study in Pediatrics found no significant difference in ...

Two-Drug Combo Helps Teens With Migraines - US News and World Report

Because the combination of Imitrex (sumatriptan) and naproxen sodium (Aleve and other brand names) isn't approved for use by the U.S. Food and Drug Administration for this age group, doctors must prescribe it "off label" to adolescents.

Pharmacokinetics and Tolerability of Rizatriptan in Pediatric Migraineurs in a Randomized Study - Medscape News

No triptans are approved in those under 12, and only sumatriptan nasal spray (European Union) and almotriptan tablets (USA) are approved for those aged 12–17. Appropriate dose selection based on body weight may be a factor in establishing ...

POZEN (POZN) Enters MT 400 Licensing Deal with Desitin Arzneimittel - StreetInsider.com

MT 400 is POZEN’s proprietary combination of sumatriptan and naproxen sodium, the first multiple mechanism triptan therapy for the treatment of migraine. POZEN previously licensed rights of the same dosage strength of MT 400 to Cilag GmbH International ...

Pozen Shares On The Rebound Since European Migraine Licensing Deal - Seekingalpha.com

MT 400 is Pozen's proprietary combination of sumatriptan and naproxen sodium, the first multiple mechanism triptan therapy for the treatment of migraine. Q: What do investors need to know about this news? How does this deal change your financial forecast ...

NuPathe Announces First Quarter 2012 Financial Results and Operational Highlights - msnbc.com

In January, the USPTO issued a notice of allowance for U.S. Patent application 12/142,604 entitled "Pharmacokinetics of Iontophoretic Sumatriptan Administration." This application relates to methods of treating a migraine by administering ...